A. M. Pappas & Associates + Chiesi Ventures Working Together

The Chiesi Group is launching its venture capital fund, Chiesi Ventures, via a strategic collaboration with A. M. Pappas & Associates. The purpose of the fund is to invest in early stage orphan and rare disease opportunities and expand the Chiesi network in the US among universities, venture capital investors, rare disease patient organizations and entrepreneurial companies developing treatments for rare diseases.

Chiesi chose to work with A. M. Pappas & Associates because of our proven experience and solid investment track record in building companies that are developing therapies for orphan and rare diseases. Chiesi Ventures will leverage our expertise and network to access and assess deals and opportunities, lead investments and manage transactions. By specifically focusing on rare diseases, it shows our ongoing commitment to drive innovation to address unmet medical needs.

> Download the Full Press Release

Built Upon a Strong Foundation

Since 1994, A. M. Pappas & Associates has been investing in and nurturing promising companies, products, technologies, ventures and other significant entrepreneurial opportunities. Currently, we have $350 million in capital under management and have invested in more than 65 portfolio companies in the United States and Canada. While our focus is on delivering superior results to investors and entrepreneurs, the firm also supports philanthropic interests in the realms of life sciences, public education and entrepreneurial endeavors.

Dedicated to the Development of Life Science Innovation

A. M. Pappas & Associates manages three lines of business:

  • Pappas Ventures – We manage a family of life science venture capital funds, whose portfolio companies include Ultragenyx Pharmaceutical (2014 IPO), Chimerix (2013 IPO), TESARO (2012 IPO), TYRX (sold to Medtronic in 2013), and Lumena Pharmaceuticals (sold to Shire in 2014). Pappas Ventures invests throughout the United States and is one of the largest dedicated life science funds in the Southeast.
  • Specialized Fund Management – We leverage our experience, expertise and network on behalf of highly targeted investment fund opportunities, with a focus initially on rare diseases. The first specialized fund in our portfolio is the Chiesi Ventures fund.
  • Translational Medicine Initiatives – We envision an opportunity to place A. M. Pappas & Associates at the nexus between researchers, university tech transfer offices, pharmaceutical companies, and disease-focused philanthropic organizations – to select, guide, and manage academic-based translational product candidates to early development milestones that will attract private investment or  industry interest.
> For more information, contact info@ampappas.com